nafronyl has been researched along with Retinal Degeneration in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Safars, M | 1 |
| Jeanny, JC | 1 |
| Mosnier, M | 1 |
| Courtois, Y | 1 |
1 other study available for nafronyl and Retinal Degeneration
| Article | Year |
|---|---|
Protection against light-induced retinal degeneration with naftidrofuryl (Praxilene) in the rat.
Topics: Animals; Injections, Intraperitoneal; Light; Male; Nafronyl; Photoreceptor Cells; Rats; Retina; Reti | 1997 |